EpiCor Clinical Study on Rapid Immune Modulating Effects

Sponsor
Cargill (Industry)
Overall Status
Not yet recruiting
CT.gov ID
NCT05819424
Collaborator
Natural Immune Systems Inc (Other)
30
1
2
6
5

Study Details

Study Description

Brief Summary

Clinical verification study evaluating the effects of a nutraceutical product. This study involves thirty participants composed of healthy adults, who will be taking either a placebo or nutraceutical supplement at different times. Testing for immune status, cytokine levels, and immune responsiveness will be conducted to determine the acute impact of the nutraceutical on immune function compared to a placebo.

Condition or Disease Intervention/Treatment Phase
  • Dietary Supplement: Yeast Fermentate (EpiCor)
N/A

Detailed Description

Clinical study comparing the acute immune effect of a nutraceutical product and a placebo. The nutraceutical supplement is a postbiotic whole food fermentate produced using yeast.

30 subjects will participate in a placebo-controlled, double-blind, randomized, cross-over design, wherein they will be taking a placebo, or nutraceutical product, each separated by a 1-week washout period to evaluate effects within 3 hours of consumption.

Blood samples will be taken 1 hour after participants arrive, then the dose is administered. Samples are taken 1 hour, 2 hours, and 3 hours following administration.

A series of immune panels will be used to determine the acute impacts on immune surveillance, immune cell activation status, and cytokine profiles. Ex vivo immune challenges will be used to determine the direct impacts on immune cells.

Study Design

Study Type:
Interventional
Anticipated Enrollment :
30 participants
Allocation:
Randomized
Intervention Model:
Crossover Assignment
Intervention Model Description:
Placebo-controlled, randomized, double-blind, cross-over design.Placebo-controlled, randomized, double-blind, cross-over design.
Masking:
Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Primary Purpose:
Basic Science
Official Title:
EpiCor Clinical Study on Rapid Immune Modulating Effects
Anticipated Study Start Date :
Apr 1, 2023
Anticipated Primary Completion Date :
Aug 1, 2023
Anticipated Study Completion Date :
Oct 1, 2023

Arms and Interventions

Arm Intervention/Treatment
Experimental: Placebo intervention first and Active intervention one week later

Participants will be consuming a placebo on a clinic day at least one week prior to a clinic day where they will consume the active intervention.

Dietary Supplement: Yeast Fermentate (EpiCor)
Dietary Supplement: Yeast Fermentate (EpiCor): Postbiotic whole food fermentate made using yeast. Composed of proteins, polyphenols, vitamins, minerals, amino acids, polysaccharides, fibre, and other nutrients. Placebo: Substance with no therapeutic value to facilitate blinding

Experimental: Active intervention first and Placebo intervention one week later

Participants will be consuming active intervention on a clinic day at least 1 week prior to a clinic day where they will consume the placebo.

Dietary Supplement: Yeast Fermentate (EpiCor)
Dietary Supplement: Yeast Fermentate (EpiCor): Postbiotic whole food fermentate made using yeast. Composed of proteins, polyphenols, vitamins, minerals, amino acids, polysaccharides, fibre, and other nutrients. Placebo: Substance with no therapeutic value to facilitate blinding

Outcome Measures

Primary Outcome Measures

  1. Immune Surveillance [At 1, 2, and 3 hours]

    Observation of changes in immune cell trafficking and status of immune cell alertness, i.e., the changes in immune cell populations and activation following administration

Secondary Outcome Measures

  1. Immune Communication [At 1, 2, and 3 hours]

    Serum cytokine levels as assessed by changes in cytokine levels individually versus placebo

Other Outcome Measures

  1. Immune Responsiveness [At 1, 2, and 3 hours]

    Ex vivo immune challenges, observing the capabilities of anti-bacterial and anti-viral defenses. Additionally, mucosal immune protection as determined by salivary IgA, defensins, and transferrin changes.

Eligibility Criteria

Criteria

Ages Eligible for Study:
18 Years to 60 Years
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
Yes
Inclusion Criteria:
  • Healthy adults of any gender

  • BMI between 18 and 30 (inclusive)

  • Veins easy to see in one or both arms (to allow for multiple blood draws)

  • Willing to comply with a 24-h wash-out period for vitamins and nutritional supplements

  • Willing to comply with study procedures including: maintaining a consistent diet and lifestyle routine throughout the study; consistent habit of bland breakfasts on days of clinic visits; abstaining from exercising and nutritional supplements on the morning of the study visit; abstaining from use of coffee, tea, and soft drinks for at least one hour prior to a clinic visit; abstaining from music, candy, bum, computer/cell phone use, during clinic visits.

Exclusion Criteria:
  • Previous major gastrointestinal surgery (absorption of test product may be altered) (minor surgery not a problem, including previous removal of appendix and gall bladder)

  • Currently in intensive athletic training (such as marathon runners)

  • Currently taking antidepressant or tranquilizing medications

  • Taking anti-inflammatory medications on a daily basis

  • Currently experiencing intense stressful events/life changes that could negatively affect compliance

  • Anything that the investigator judges may put the subject at risk or may unduly influence any of the results of the study

  • An unusual sleep routine (examples: working nightshift, irregular routine with frequent late nights)

  • Unwilling to maintain a constant intake of supplements over the duration of the study

  • Anxiety about having blood drawn

  • People of childbearing potential: pregnant, nursing, or trying to become pregnant

  • Known food allergies related to ingredients in active test product or placebo

Prescription medication will be evaluated on case-by-case basis.

Contacts and Locations

Locations

Site City State Country Postal Code
1 NIS Labs Klamath Falls Oregon United States 97601

Sponsors and Collaborators

  • Cargill
  • Natural Immune Systems Inc

Investigators

  • Principal Investigator: Gitte Jensen, PhD, NIS Labs

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.
Responsible Party:
Cargill
ClinicalTrials.gov Identifier:
NCT05819424
Other Study ID Numbers:
  • 004-044
First Posted:
Apr 19, 2023
Last Update Posted:
Apr 20, 2023
Last Verified:
Apr 1, 2023
Individual Participant Data (IPD) Sharing Statement:
No
Plan to Share IPD:
No
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
No

Study Results

No Results Posted as of Apr 20, 2023